secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007036
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q4 revenue flat at $15.2M; record glaucoma probe sales; FY net loss widens to $7.5M
--------------------------------------------------------------------------------

- Q4 revenue $15.2M (flat YoY); net loss improved to $1.1M ($0.07/sh) from $2.4M loss.
- FY2022 revenue $57.0M (+6% YoY); net loss $7.5M ($0.47/sh) vs $5.2M ($0.34) in 2021.
- Record Cyclo G6 probe sales: 16,400 units in Q4 (+8% YoY); Q4 glaucoma product revenue $4.2M (+9%).
- Retina revenue $8.1M in Q4 (-11% YoY); full-year retina $31.7M (+2%).
- 2023 guidance: revenue $57-59M; Cyclo G6 probes 65k-67k units (9-12% growth); adjusting for ~$1.5M royalty reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/irix-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer